Coherus Oncology, Inc.

Coherus Oncology, Inc.

0.48
USD
-0.03
(-5.42%)
-1.22EPS
216.26MMarket Cap
Mar 15Next Earn

Coherus Oncology, Inc. Documents

Q1 FY2025 · Presentation

Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors · 37 pages

Read Coherus Oncology, Inc.'s results firsthand

Preview the first 2 pages of this presentation
Create a free account to start reading

Full documents are included with Professional

Q1 FY2025 documents